SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ken Hays who wrote (120)6/19/1997 8:59:00 PM
From: r. peter Dale   of 4474
 
Ken: In the biomedical sciences, In Vitro almost always means outside the body. In Vivo implies within the body. The significance of the distinction of these terms is important for drug studies: when reports refer to In Vitro experiments, this usually suggests a drug was tested on a population of cells, or a small chunk of tissue, grown in a dish under sterile conditions. The point of the experiment is to measure something following the drug exposure which the researcher believes will be effected by the drug (i.e. change in the expression of a protein of interest). The advantages are that you have highly controlled conditions and either a homogeneous or restricted-heterogeneous cell population. The disadvantage is that its incredibly artificial. In Vivo work can be viewed as the mirror image of this: uncontrolled conditions in a realistic environment. Working with animals is often a pain due to the multitude of potential interations. It does have the clear benefit of feeding humble pie to the vast majority of those claiming 'magic bullet' cures.

This is why the issue of targeting and drug specificity is so important: since Ariad is targeting a part of a protein(s) that is common to many other proteins, if their drugs aren't exquisitely specific, well, we have a problem Houston.

I gotta go.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News